BeiGene
BGNE
#882
Rank
HK$178.75 B
Marketcap
HK$1,597
Share price
-0.65%
Change (1 day)
2.73%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Cash on Hand

Cash on Hand as of June 2024 : HK$20.15 Billion

According to BeiGene 's latest financial reports the company has HK$20.15 Billion in cash and cash equivalents.
A companyโ€™s cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.

BeiGene - Cash on Hand chart (from 2014 to 2024)

Cash on Hand by year

Year Cash on Hand Change
2023-12-31HK$24.79 B-30.03%
2022-12-31HK$35.43 B-31.34%
2021-12-31HK$51.60 B43.13%
2020-12-31HK$36.05 B371.05%
2019-12-31HK$7.65 B-45.14%
2018-12-31HK$13.95 B113.19%
2017-12-31HK$6.54 B129.19%
2016-12-31HK$2.85 B266.57%
2015-12-31HK$0.77 B126.18%
2014-12-31HK$0.34 B1031.1%
2013-12-31HK$30.44 M

Cash on Hand for similar companies or competitors

Company Cash on Hand differencediff. Country
HK$0.12 B-99.37%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$0.31 B-98.43%๐Ÿ‡บ๐Ÿ‡ธ USA